If you read our state-by-state psilocybin reality check back in August, the first half of November added several new dates to that story. Voters weighed in on Nov. 3, Compass Pathways completed its psilocybin drug application on Nov. 9, and on Nov. 12 the federal government announced new research money for ibogaine. Here is what happened, with every figure dated and sourced. Nothing here is medical advice, and none of it changes what is legal where you live.
Idaho Says No to HJR 4
The biggest psychedelics-related vote on Nov. 3 was not a legalization measure at all. Idaho's House Joint Resolution 4 asked voters to amend the state constitution so that "only the Idaho Legislature" could legalize marijuana, narcotics or "other psychoactive substances." That would have taken the question away from citizen ballot initiatives.
Voters rejected it. Unofficial results from the Idaho Secretary of State, last updated Nov. 10, show 472,957 votes against (66.26%) and 240,832 in favour (33.74%). The result keeps the initiative route open in Idaho. It does not legalize anything.
Three Oregon Towns Keep Psilocybin Businesses Out
Oregon voters approved licensed psilocybin services through Measure 109 in 2020, but local voters can still keep those businesses out of their towns, and some keep doing so.
- Redmond extended its moratorium on psilocybin service centers for another two years. Deschutes County's unofficial results, updated Nov. 13, show Measure 9-186 passing 8,870 to 6,813 (56.56%). The Redmond Spokesman notes it is the third time city voters have backed a moratorium, after 53% in 2022 and 55% in 2024.
- Reedsport approved Measure 10-215, a ban on psilocybin-related businesses, with about 65.5% voting yes in unofficial Oregon Secretary of State figures reported by KOBI-TV on Nov. 10.
- Joseph voted 414 to 279 to continue its ban on psilocybin-related businesses, according to unofficial results reported by the Wallowa County Chieftain.
All of these counts are unofficial until certified.
Compass Completes Its Psilocybin NDA
On Nov. 9, Compass Pathways announced that it had finished submitting its New Drug Application to the U.S. FDA for COMP360, its synthetic psilocybin formulation, for treatment-resistant depression. The company says the filing draws on two Phase 3 trials and a Phase 2b study with more than 1,000 participants in total. It is planning for a U.S. launch in the first half of 2027, subject to FDA approval.
Two cautions belong right next to that headline. First, a filing is not an approval. Psychiatric Times notes that if it is approved, COMP360 would be the first classic psychedelic medicine the FDA has ever approved. Second, psilocybin is still a Schedule I controlled substance under federal law, so, as Drug Discovery & Development reports, the DEA would have to reschedule it before any launch, and state rules could affect where it is available.
Compass is not alone. Trade publication Psychedelic Alpha reported on Nov. 2, citing sources, that the nonprofit Usona Institute had filed its own psilocybin application for major depressive disorder. Usona declined to comment on that report.
The Fast-Track Question
Both Compass and Usona hold Commissioner's National Priority Vouchers, an FDA pilot program meant to cut some reviews to one or two months. On Nov. 12, Reuters reported, citing six sources and internal documents, that the FDA has shelved that program and has awarded no new vouchers since former Commissioner Marty Makary left in May. An HHS spokesperson told Reuters the pilot is ongoing. Psychedelic Alpha expects the FDA to try to honour existing vouchers but says it is not yet clear how things will proceed. In short, the timing of any decision is uncertain.
HHS Puts Money Into Ibogaine Groundwork
Also on Nov. 12, HHS announced up to $4.9 million over five years through ARPA-H to prepare ibogaine for possible future U.S. studies in PTSD. The teams are led by the Mark Cuban Cost Plus Drug Company and Beond, Inc. HHS is explicit about the limits: the money funds regulatory and manufacturing groundwork, not patient treatment or human-subject research, and it does not authorize clinical trials or establish FDA approval. HHS also states plainly that ibogaine carries serious safety risks, including potentially life-threatening heart rhythm problems.
Separately, the National Institute of Mental Health posted a $20 million funding opportunity for a research network on rapid-acting psychotropic drugs, including ketamine, esketamine and psilocybin. Awards are expected in summer 2027.
What This Means for Psychedelic Culture
None of this changes the law for an individual in most of the U.S., and, as the ROM notes, most psychedelics remain illegal in Canada. What it does change is the conversation. Psychedelic art and trippy clothing have always borrowed from the same visual language that is now showing up in courtrooms, ballot booklets and federal press releases. That language includes mandalas, fractals and sacred geometry. We will keep tracking the facts, and we will keep making room for the art.
Wear the Art, Follow the Story
The Salvia Droid designs in our shop carry that visionary imagery into everyday layers:
- THE GOD SOURCE Microfleece Cloak by Salvia Droid
- THE GOD SOURCE Zipper Hoodie by Salvia Droid
- RISE TO THE CALL Zipper Cloak, Deluxe Edition by Salvia Droid
- ENTITY Microfleece Cloak by Salvia Droid
Shop psychedelic art you can wear at acidmath.com, where every design comes from an artist we work with directly.
Sources
- Idaho Secretary of State, General Election Nov. 3, 2026, unofficial results (State Measures), last updated Nov. 10, 2026: https://results.voteidaho.gov/results/public/id/elections/nov2026?cg=State+Measures
- Deschutes County Clerk, unofficial results for the 11/3/2026 General Election, updated Nov. 13, 2026: https://webapps.deschutes.org/Elections/Home/Results
- Redmond Spokesman, "Redmond extends psilocybin service center moratorium a third time," Nov. 3, 2026: https://redmondspokesman.com/2026/11/03/redmond-extends-psilocybin-service-center-moratorium-a-third-time/
- KOBI-TV NBC5, Reedsport Measure 10-215 results (Oregon SOS data as of Nov. 10, 2026): https://kobi5.com/elections-coverage/oregon/measure-10-215-bans-the-establishment-of-psilocybin-related-businesses/
- Wallowa County Chieftain, "Election 2026 Update: Joseph continues psilocybin ban," Nov. 4, 2026: https://wallowa.com/2026/11/03/election-2026-joseph-votes-to-continue-psilocybin-ban-other-results/
- Compass Pathways, press release, Nov. 9, 2026: https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx
- Psychiatric Times, "NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression," Nov. 9, 2026: https://www.psychiatrictimes.com/view/nda-submission-complete-comp360-psilocybin-for-treatment-resistant-depression
- Drug Discovery & Development, "Compass files psilocybin NDA with FDA as rivals close in," Nov. 9, 2026: https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/
- Psychedelic Alpha, Psychedelic News Feed, editor's notes for Nov. 2–8 and Nov. 9–15, 2026: https://psychedelicalpha.com/live/
- Reuters (via Yahoo News), "Exclusive-US FDA shelves commissioner's voucher program for speedy drug reviews, sources say," Nov. 12, 2026: https://www.yahoo.com/news/politics/articles/exclusive-us-fda-shelves-commissioners-110541639.html
- U.S. HHS, press release, Nov. 12, 2026: https://www.hhs.gov/press-room/hhs-advances-ibogaine-ptsd-research-rapid-acting-mental-health-treatments.html
- Royal Ontario Museum, news release, May 28, 2026 (note on legality in Canada): https://www.rom.on.ca/news-releases/innovative-new-exhibition-exploring-art-culture-and-science-psychedelics-opens-rom